Back to Search
Start Over
Regulatory role of transcription factor HBP1 in anticancer efficacy of EGFR inhibitor erlotinib in HNSCC.
- Source :
-
Head & neck [Head Neck] 2020 Oct; Vol. 42 (10), pp. 2958-2967. Date of Electronic Publication: 2020 Jul 17. - Publication Year :
- 2020
-
Abstract
- Background: Epidermal growth factor receptor (EGFR) is often hyperactivated in head and neck squamous cell carcinoma (HNSCC); however, its downstream mediators are not fully identified. Here, we investigate the role of transcription factor HBP1 in the anticancer efficacy of EGFR inhibitor erlotinib in HNSCC.<br />Methods: The effect of erlotinib and HBP1 on cell proliferation and invasion was examined by flow cytometric analysis and a Matrigel invasion assay, respectively. Oral tumor specimens were used to evaluate the association between the expression level of EGFR and HBP1, and metastatic potential.<br />Results: Erlotinib caused cell growth arrest in the G1 phase and sluggish invasion with a concomitant increase in HBP1 and p27 expression. The erlotinib effect was attenuated upon HBP1 knockdown. Analysis of oral tumor specimens revealed that the low HBP1/high EGFR status can predict metastatic potential.<br />Conclusions: Our data support HBP1 as a crucial mediator of EGFR-targeting inhibitors in HNSCC.<br /> (© 2020 Wiley Periodicals LLC.)
- Subjects :
- Cell Line, Tumor
ErbB Receptors genetics
Erlotinib Hydrochloride pharmacology
High Mobility Group Proteins
Humans
Repressor Proteins
Squamous Cell Carcinoma of Head and Neck drug therapy
Squamous Cell Carcinoma of Head and Neck genetics
Transcription Factors
Carcinoma, Squamous Cell drug therapy
Carcinoma, Squamous Cell genetics
Head and Neck Neoplasms drug therapy
Head and Neck Neoplasms genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1097-0347
- Volume :
- 42
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Head & neck
- Publication Type :
- Academic Journal
- Accession number :
- 32677158
- Full Text :
- https://doi.org/10.1002/hed.26346